NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
OR — îòíîøåíèå øàíñîâ (odds ratio)
paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé ðåâìàòîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:
Arnalda C, Terreri MT, Puccini RF, et al: Development of a tool for early referral of children and adolescents with signs and symptoms suggestive of chronic arthropathy to pediatric rheumatology centers, Arthritis Rheum 55:373–377, 2006.
Breda L, Nozzi M, De Sanctis S, et al: Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update, Semin Arthritis Rheum 40(1):53–72, 2010.
Giancane G, Consolaro A, Lanni S, et al: Juvenile idiopathic arthritis: diagnosis and treatment, Rheumatol Ther 3(2):187–207, 2016.
Jones OY, Spencer CH, Bowyer SL, et al: A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis, Pediatrics 117:e840–e844, 2006.
Junnila JL, Cartwright VW: Chronic musculoskeletal pain in children. Part I. Initial evaluation, Am Fam Physician 74:115–122, 2006.
Junnila JL, Cartwright VW: Chronic musculoskeletal pain in children. Part II. Rheumatic causes, Am Fam Physician 74:293–300, 2006.
McGhee JL, Kickingbird LM, Jarvis JN: Clinical utility of antinuclear antibody tests in children, BMC Pediatr 4:13–18, 2004.
Reyhan I, Goldberg BR, Gottlieb BS: Common presentations of pediatric rheumatologic diseases: a generalist’s guide, Curr Opin Pediatr 25:388–396, 2013.
Weiss PF: Imaging: enhanced evaluation of children and adults with rheumatic disease, Rheum Dis Clin North Am 42(4):xv–xvi, 2016.
Ardoin S, Schanberg LE: The management of pediatric systemic lupus erythematosus, Nat ClinPractRheumatol 1:1–11, 2005.
Beukelman T, Patkar NM, Saag KG, et al: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care Res (Hoboken) 63(4):465–482, 2011.
Clinical pharmacology [online database], Tampa FL, 2017, Gold Standard.
Davies R, Gaynor D, Hyrich KL, Pain CE: Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review, Semin Arthritis Rheum 46(5):584–593, 2017.
Feldman BM, Rider LG, Reed AM, et al: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood, Lancet 371:2201–2212, 2008.
Gelfand EW: Intravenous immune globulin in autoimmune and inflammatory diseases, N Engl J Med 367:2015–2024, 2012.
Giancane G, Consolaro A, Lanni S, et al: Juvenile idiopathic arthritis: diagnosis and treatment, RheumatolTher 3(2):187–207, 2016.
Gowdie PJ, Tse S: Juvenile idiopathic arthritis, PediatrClin North Am 59:301–327, 2012.
Hashkes PJ, Becker ML, Cabral DA, et al: Methotrexate: new uses for an old drug, J Pediatr 164(2):231–236, 201, 2014.
Haske G, Cronstein B: Regulation of inflammation by adenosine, Front Immunol 4:1–8, 2013.
Kahn P: Juvenile idiopathic arthritis: an update for the clinician, Bull NYU HospJt Dis 70:152–166, 2012.
Mannion ML, Beukelman T: Risk of malignancy associated with biologic agents in pediatric rheumatic disease, CurrOpinRheumatol 26(5):538–542, 2014.
Mannion ML, Xie F, Baddley J, et al: Analysis of health care claims in the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients, PediatrRheumatol Online J 14(1):49, 2016.
McGonagh JE: Young people first, juvenile idiopathic arthritis second: transitional care in rheumatology, Arthritis Rheum 59:1162–1170, 2008.
Morishita K, Brown K, Cabral D: Pediatric vasculitis: advances in treatment, CurrOpinRheumatol 27(5):493–499, 2015.
Navaneethan SD, Viswanathan G, Strippoli GF: Treatment options for proliferative lupus nephritis: an update of clinical trial evidence, Drugs 68:2095–2104, 2008.
Nigrovic PA, Mannion M, Prince F, et al: Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis, Arthritis Rheum 63:545–555, 2011.
Shum K, Askanase A: Belimumab and the clinical data, CurrRheumatol Rep 14:310–317, 2012.
Sobel RE, Lovell DJ, Brunner HI, et al: Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry, PediatrRheumatol Online J 12:29, 2014.
Sterba Y, Ilowite N: Biologics in pediatric rheumatology: quo vadis, CurrRheumatol Rep 18(7):45, 2016.
Behrens EM, Beukelman T, Gallo L, et al: Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR), J Rheumatol 35:343–348, 2008.
Beukelman T, Patkar NM, Saag KG, et al: American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care Res 63:465–482, 2011, 2011.
Brunner HI, Ruperto N, Zuber Z, et al: Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial, Ann Rheum Dis 74:1110–1117, 2015.
Burmester GR, Panaccione R, Gordon KB, et al: Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease, Ann Rheum Dis 72:517–524, 2013.
Burmester GR, Pope JE: Novel treatment strategies in rheumatoid arthritis, Lancet 389:2338–2346, 2017.
Cassidy J, Kivlin J, Lindsley C, et al: Ophthalmologic examinations in children with juvenile rheumatoid arthritis, Pediatrics 117:1843–1845, 2006.
Cavello S, Brousseau L, Toupin-April K, et al: Ottawa Panel evidence-based clinical practice guidelines for structured physical activity in the management of juvenile idiopathic arthritis, Arch Phys Med Rehabil 98(5):1018–1041, 2017.
Clark SLN, Sen ES, Ramanan AV: Juvenile idiopathic arthritis–associated uveitis, Pediatr Rheumatol 14:27, 2016.
DeWitt EM, Kimura Y, Beukelman T, et al: Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis, Arthritis Care Res 64:1001–1010, 2012.
Dougados M, Baeten D: Arthritis. 2. Spondyloarthritis, Lancet 377:2127–2134, 2011.
Foell D, Wulffraat N, Wedderburn LR, et al: Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission, JAMA 303:1266–1273, 2010.
Fox DA: Kinase inhibition: a new approach to the treatment of rheumatoid arthritis, N Engl J Med 367:565–566, 2012.
Gowdie PJ, Tse SM: Juvenile idiopathic arthritis, Pediatr Clin North Am 59:301–372, 2012.
Hersh AO, Prahalad S: Immunogenetics of juvenile idiopathic arthritis: a comprehensive review, J Autoimmun 64:113–124, 2015.
Grom AA: Primary hemophagocytic lymphohistiocytosis and macrophage activation syndrome: the importance of timely clinical differentiation, J Pediatr 189:19–21, 2017.
Guzman J, Henrey A, Loughlin T, et al: Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCH-Out cohort, J Rheumatol 44(2):230–240, 2017.
Kaufman KM, Linghu B, Szustakowski JD, et al: Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphophistiocytosis, Arthritis Rheumatol 66(12):3486–3495, 2014.
LeBovidge JS, Lavigne JV, Donenberg GR, et al: Psychological adjustment of children and adolescents with chronic arthritis: a meta-analytic review, J Pediatr Psychol 28:29–39, 2003.
Lovell DJ, Ruperto N, Mouy R, et al: Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years, Arthritis Rheumatol 67:1759–2770, 2015.
McInnes IB, Schett G: Pathogenetic insights from the treatment of rheumatoid arthritis, Lancet 389:2328–2336, 2017.
The Medical Letter: Tofacitinib (Xeljanz) for rheumatoid arthritis, Med Lett Drugs Ther 55(1407):1–4, 2013.
Minoia F, Bovis F, Davi S, et al: Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that differentiates primary hemophagocytic lymphohistiocytosis from macrophage activation syndrome, J Pediatr 189:72–78, 2017.
Petty RE, Southwood TR, Manners P, et al: International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis: second revision, Edmonton, J Rheumatol 31:390–392, 2004, 2001.
Prince FHM, Otten MH, van Suijlekom-Smit WA: Diagnosis and management of juvenile idiopathic arthritis, BMJ 342:95–102, 2011.
Ramanan AV, Dick AD, Jones AP, et al: Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis, N Engl J Med 376(17):1637–1646, 2017.
Ravelli A, Grom A, Behrens E, et al: Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment, Genes Immun 13:289–298, 2012.
Ravelli A, Minoia F, Dav? S, et al: Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative, Arthritis Rheumatol 68:566–576, 2016.
Ringold S, Weiss PF, Colbert RA, et al: Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis, Arthritis Care Res 66:1063–1072, 2014.
Scott DL, Stevenson MD: Treating active rheumatoid arthritis with Janus kinase inhibitors, Lancet 390:431–432, 2017.
Shenoi S, Wallace CA: Diagnosis and treatment of systemic juvenile idiopathic arthritis, J Pediatr 177:19–26, 2016.
Sikora KA, Grom AA: Update on the pathogenesis and treatment of systemic idiopathic arthritis, Curr Opin Pediatr 23:640–646, 2011.
Toussi SS, Pan N, Walters HM, Walsh TJ: Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-? inhibitors: systematic review of the literature, Clin Infect Dis 57:1318–1330, 2013.
Ungar WJ, Costa V, Burnett HF, et al: The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review, Semin Arthritis Rheum 42:597–618, 2013.
Wittkowski H, Frosch M, Wulffraat N, et al: S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin, Arthritis Rheum 58:3924–3931, 2008.
Ellinghaus D, Jostins L, Spain SL, et al: Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci, Nat Genet 48(5):510–518, 2016.
Gladman D, Rigby W, Azevedo VF, et al: Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors, N Engl J Med 377(16):1525–1536, 2017.
Hugle B, Burgos-Vargas R, Inman RD, et al: Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis, Clin Exp Rheumatol 32(3):424–431, 2014.
Nash P, Kirkham B, Okada M, et al: Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomized, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial, Lancet 389:2317–2326, 2017.
Ritchlin CT, Colbert RA, Gladman DD: Psoriatic arthritis, N Engl J Med 376(10):957–970, 2017.
Rohekar S, Chan J, Tse SML: 2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I. Principles of the management of spondyloarthritis in Canada, J Rheumatol 42(4):654–664, 2015.
Sherlock JP, Taylor PC, Buckley CD, Cua DJ: Spondyloarthropathy: interleukin 23 and disease modification, Lancet 385:2017–2018, 2015.
Taurog JD, Chhabra A, Colbert RA: Ankylosing spondylitis and axial spondylitis, N Engl J Med 374(26):2563–2574, 2016.
Taurog JD, Chhabra A, Colbert RA: Ankylosing spondylitis and axial spondyloarthritis, N Engl J Med 374(26):2563–2572, 2016.
Tse SML, Petty RE: Enthesitis related arthritis. In Petty RE, Laxer R, Lindsley CB, et al, editors: Textbook of pediatric rheumatology, ed 7, Philadelphia, 2015, Saunders Elsevier.
Van der Heijde D, Ramiro S, Landewe R, et al: 2016 Update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis 76(6):978–991, 2017.
Ward M, Deodhar A, Akl E, et al: American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis, Arthritis Rheumatol 68(2):282–298, 2016.
Weiss PF, Xiao R, Biko DM, et al: Assessment of sacroiliitis at diagnosis of juvenile spondyloarthritis by radiography, magnetic resonance imaging, and clinical examination, Arthritis Care Res (Hoboken) 68(2):187–194, 2016.
Aupiais C, Ilharreborde B, Doit C, et al: Aetiology of arthritis in hospitalized children: an observational study, Arch Dis Child 100(8):742–747, 2015.
Burgos-Vargas R, Vazquez-Mellado J: Reactive arthritis. In Petty RE, Laxer R, Lindsley CB, et al, editors: Textbook of pediatric rheumatology, ed 7, Philadelphia, 2015, Saunders Elsevier.
Generali E, Ceribelli A, Massarotti M, et al: Seronegative reactive spondyloarthritis and the skin, Clin Dermatol 33(5):531–537, 2015.
Hannu T: Reactive arthritis, Best Pract Res ClinRheumatol25:347–357, 2011.
Horton DB, Strom BL, Putt ME, et al: Epidemiology of Clostridium difficile infection-associated reactive arthritis in children: an underdiagnosed, potentially morbid condition, JAMA Pediatr170(7):e160217, 2016.
Selmi C, Gershwin ME: Diagnosis and classification of reactive arthritis, Autoimmun Rev 13(4–5):546–549, 2014.
Stavropoulos PG, Soura E, Kanelleas A, et al: Reactive arthritis, J EurAcadDermatolVenereol29(3):415–424, 2015.
Abeles AM, Abeles M: The clinical utility of a positive antinuclear antibody test result, Am J Med 126:342–348, 2013
Alpert O, Marwaha R, Huang H: Psychosis in children with systemic lupus erythematosus: the role of steroids as both treatment and cause, Gen Hosp Psychiatry 36:549.e1–549.e2, 2014
Arbuckle MR, McClain MT, Rubertone MV, et al: Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N Engl J Med 346(16):1526–1533, 2003
Ardoin SP, Schanberg LE, Sandborg CI, et al: Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein, Ann Rheum Dis 73(3):557–566, 2014
Arace ZS, Batu ED, Ozen S: Reviewing the recommendations for lupus in children, CurrRheumatol Rep 17(3):2015
Bertsias GK, Tektonidou M, Amoura Z, et al: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, Ann Rheum Dis 71(11):1771–1782, 2012
Bordia RE, Silverman ED: Childhood-onset systemic lupus erythematosus: an update, CurrOpinRheumatol27(5):483–492, 2015
Davis LS, Hutcheson J, Mohan C: The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus, J Interferon Cytokine Res 31(10):781–789, 2011
Groot N, de Graeff N, Avcin T, et al: European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative, Ann Rheum Dis 76(12):1965–1973, 2017
Hahn BH: Belimumab for systemic lupus erythematosus, N Engl J Med 368(16):1528–1534, 2013
Hahn BH, McMahon MA, Wilkinson A, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care Res 64(6):797–808, 2012
Hedrich CM, Zappel H, Straub S, et al: Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options, ClinRheumatol30:275–283, 2011
Kamphuis S, Silverman ED: Prevalence and burden of pediatric-onset systemic lupus erythematosus, Nat Rev Rheumatol6:538–546, 2010
Kariuki SN, Niewold TB: Genetic regulation of serum cytokines in systemic lupus erythematosus, Transl Res 155(3):109–117, 2010
Kivity S, Agmon-Levin N, Zandman-Goddard G, et al: Neuropsychiatric lupus: a mosaic of clinical presentation, BMC Med 13:43, 2015
Levy DM, Ardoin SP, Schanberg LE: Neurocognitive impairment in children and adolescents with systemic lupus erythematosus, Nat ClinPractRheumatol5(2):106–114, 2009.
Levy DM, Kamphuis S: Systemic lupus erythematosus in children and adolescents, PediatrClin North Am 59(2):345–364, 2012
Liu Z, Davidson A: Taming lupus: a new understanding of pathogenesis is leading to clinical advances, Nat Med 18(6):871–880, 2012
Mina R, von Scheven E, Ardoin SP, et al: Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus, Arthritis Care Res 64(3):375–383, 2012
Nanthapisal S, Omoyinmi E, Murphy C, et al: Early-onset juvenile SLE associated with a novel mutation in protein kinase C ?, Pediatrics 139(1):e20160781, 2017.
Petri M, Orbai AM, Alarcon GS, et al: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum 64(8):2677–2686, 2012.
Pineles A, Valente A, Warren B, et al: Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus, Lupus 20:1187–1192, 2011
Schanberg LE, Sandborg CI, Barnhart HX, et al: Use of atorvastatin in systemic lupus erythematosus in children and adolescents, Arthritis Rheum 64(1):285–296, 2012
Silva CA, Avcin T: Brybber HI: Taxonomy for systemic lupus erythematosus with onset before adulthood, Arthritis Care Res 64(12):1787–1793, 2012
Steri M, Idda OML, Pitzalis M, et al: Overexpression of the cytokine BAFF and autoimmunity risk, N Engl J Med 376(17):1615–1626, 2017
Tang X, Huang Y, Deng W, et al: Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus, Medicine (Baltimore) 89:62–67, 2010
Thorbinson C, Oni L, Smith E, et al: Pharmacological management of childhood-onset systemic lupus erythematosus, Paediatr Drugs 18(3):181–195, 2016
Tsokos GC: Systemic lupus erythematosus, N Engl J Med 365(22):2110–2120, 2011
Tullus K: New developments in the treatment of systemic lupus erythematosus, PediatrNephrol27:727–732, 2012
Brucato A: Prevention of congenital heart block in children of SSA-positive mothers, Rheumatology 47:iii35–iii37, 2008
Clowse ME, Madger L, Witter F, et al: Hydroxychloroquine in lupus pregnancy, Arthritis Rheum 54(11):3640–3647, 2006
Crucato A, Cimaz R, Caporali R, et al: Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies, Clin Rev Allergy Immunol 40(1):27–41, 2011
Friedman DM, Kim MY, Copel JA, et al: Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study, Circulation 117(4):485–493, 2008
Friedman D, Kim MY, Copel JA, et al: Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR interval and dexamethasone evaluation (PRIDE) study, Am J Cardiol 103:1102–1106, 2009
Friedman DM, Llanos C, Izmirly PM, et al: Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial, Arthritis Rheum 63(4):1138–1146, 2010
Izmirly PM, Buyon JP, Saxena A: Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease, CurrOpinRheumatol 24(5):466–472, 2012
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al: Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro–antibody-associated cardiac manifestations of neonatal lupus, Circulation 126:76–82, 2012
Izmirly PM, Kim MY, Llanos C, et al: Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine, Ann Rheum Dis 69:1827–1830, 2010
Izmirly PM, Saxena A, Sahl SK, et al: Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro–associated cardiac injury limited to the fetal conduction system, Ann Rheum Dis 75(6):1161–1165, 2016
Klein-Gitelman MS: Neonatal lupus: what we have learned and current approaches to care, CurrRheumatol Rep 18(9):60, 2016
Li YQ, Wang Q, Luo Y, et al: Neonatal lupus erythematosus: a review of 123 cases in China, Int J Rheum Dis 18(7):761–767, 2015
Llanos C, Friedman DM, Saxena A, et al: Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus, Rheumatology 51:1086–1092, 2012
Silverman E, Jaeggi E: Non-cardiac manifestations of neonatal lupus erythematosus, Scand J Immunol 72(3):223–225, 2010
Belluti Enders F, Bader-Meunier B, Baildam E, et al: Consensus-based recommendations for the management of juvenile dermatomyositis, Ann Rheum Dis 76(2):329–340, 2017.
Bingham A, Mamyrova G, Rother KI: Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity, Medicine (Baltimore) 87:70–86, 2008.
ButbulAviel Y, Stremler R, Benseler S, et al: Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis, Rheumatology 50:2051–2060, 2011.
Dalakas MC: Inflammatory muscle diseases, N Engl J Med 372(18):1734–1746, 2015.
Deakin CT, Yasin SA, Simou S, et al: Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis, Arthritis Rheum 68:2806–2816, 2016.
Eimer MJ, Brickman WJ, Seshadri R, et al: Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis, J Pediatr159:795–801, 2011.
Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood, Lancet 371:2201–2212, 2008.
Fernandez C, Bardin N, De Paula AM, et al: Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies, Medicine (Baltimore) 92:15–24, 2013.
Fremond ML, Gitiaux C, Bonnet D, et al: Mosaic tetrasomy 9p: a mendelian condition associated with pediatric-onset overlap myositis, Pediatrics 136(2):e544–e547, 2015.
Huber AM, Robinson AB, Reed AM, et al: Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference, Arthritis Care Res 64:546–553, 2012.
Hull KM, Wong K, Wood GM, et al: Monocytic fasciitis, Arthritis Rheum 46(8):2189–2194, 2002.
Klein R, Rosenbach M, Kim EJ, et al: Tumor necrosis factor inhibitor- associated dermatomyositis, Arch Dermatol 146(7):780–784, 2010.
Labirua-Iturburu A, Selva-O’Callaghan A, Vincze M, et al: Anti-PL-7 (Anti-threonyl-tRNAsynthetase) antisynthetase syndrome, Medicine (Baltimore) 91:206–211, 2012.
de Lopez Padilla CM, Vallejo AN, McNallan KT, et al: Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis, Arthritis Rheum 56:1658–1668, 2007.
Lundberg IE: The heart in dermatomyositis and polymyositis, Rheumatology 45(iv):18–iv21, 2006.
Mamyrova G, O’Hanlon TP, Sillers L, et al: Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis, Arthritis Rheum 58:3941–3950, 2008.
Oddis CV, Reed AM, Aggarwal R, et al: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and polymyositis, Arthritis Rheum 65:314–324, 2013.
Omori CH, Silva CA, Sallum AM, et al: Exercise training in juvenile dermatomyositis, Arthritis Care Res 64:1186–1194, 2012.
Quillinan N, Mohammad A, Mannion G, et al: Imaging evidence for persistent subclinical fasciitis and arthritis in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) between febrile attacks, Ann Rheum Dis 69(7):1408–1409, 2010.
Ravelli A, Trail L, Ferrari C, et al: Long-term outcome and prognostic factors of juvenile dermatomyositis: a multifunctional, multicenter study of 490 patients, Arthritis Care Res 62:63–72, 2010.
Reed AM, McNallan K, Wettstein P, et al: Does HLA-dependent chimerism underlie the pathogenesis of juvenile dermatomyositis? J Immunol 172:5041–5046, 2004.
Rider LG, Miller FW: Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies, JAMA 305(2):183–190, 2011.
Rider LG, Nistala K: The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes, J Intern Med 280:24–38, 2016.
Ruperto N, Pistorio A, Oliveira S, et al: Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomized trial, Lancet 387:671–678, 2016.
Schwartz T, PyndtDiederichsen L, Lundberg IE, et al: Cardiac involvement in adult and juvenile idiopathic inflammatory myopathies, RMD Open 2:e000291, 2016.
Shah M, Mamyrova G, Targoff IN, et al: The clinical phenotypes of the juvenile idiopathic inflammatory myopathies, Medicine (Baltimore) 92:25–41, 2013.
Tansley SL, McHugh NJ, Wedderburn LR: Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms, Arthritis Res Ther15:211–220, 2013.
Gabrielli A, Avvedimento EV, Krieg T: Scleroderma, NEngl J Med 360:1989–2002, 2009
Gelber AC, Manno RL, Shah AA, et al: Race and association with disease manifestations and mortality in scleroderma, Medicine (Baltimore) 92(4):191–205, 2013
Goundry B, Bell L, Langtree M, et al: Diagnosis and management of Raynaud’s phenomenon, BMJ 344:37–42, 2012
Gu YS, Kong J, Cheema GS, et al: The immunobiology of systemic sclerosis, Semin Arthritis Rheum 38:132–160, 2008
Li SC, Torok KS, Pope E, et al: Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma, Arthritis Care Res 64(8):1175–1185, 2012
Pellar RE, Pope JE: Evidence-based management of systemic sclerosis: navigating recommendations and guidelines, Semin Arthritis Rheum 46(6):767–774, 2016
Scalapino K, Arkachaisri T, Lucas M, et al: Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease, J Rheumatol 33:1004–1013, 2006
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al: Myeloablative autologous stem-cell transplantation for severe scleroderma, N Engl J Med 378(1):35–46, 2018
Van Laar JM, Farge D, Sont JK, et al: Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis, JAMA 311(24):2490–2498, 2014
Wigley FM, Flavahan NA: Raynaud’s phenomenon, N Engl J Med 375(6):556–565, 2016
Arida A, Fragiadaki K, Giavri E, et al: Anti-TNF agents for Beh?et’s disease: analysis of published data on 369 patients, Semin Arthritis Rheum 41:61–70, 2011.
Cook AL, Rouster-Stevens K, Williams DA, et al: Giant aneurysm of the left anterior descending coronary artery in a pediatric patient with Behcet’s disease, Pediatr Cardiol 31:700–702, 2010.
Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al: Colchicine versus placebo in Beh?et’s disease: randomized, double-blind, controlled crossover trial, Mod Rheumatol 19:542–549, 2009.
Eldem B, Onur C, Ozen S: Clinical features of pediatric Beh?et’s disease, J Pediatr Ophthalmol Strabismus 35:159–161, 1998.
Hatemi G, Silman A, Bang D, et al; EULAR Expert Committee: EULAR recommendations for the management of Beh?et disease, Ann Rheum Dis 67:1656–1662, 2008.
Hatemi G, Melikoglu M, Tunc R, et al: Apremilast for Beh?et’s syndrome—a phase 2 placebo controlled study, N Engl J Med 372:1510–1518, 2015.
International Study Group for Beh?et’s Disease: Criteria for diagnosis of Beh?et’s disease, Lancet 335:1078–1080, 1990.
Jennette JC, Falk RJ, Bacon PA, et al: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Arthritis Rheum 65:1–11, 2013.
Kirino Y, Bertsias G, Ishigatsubo Y, et al: Genome-wide association analysis identifies new susceptibility loci for Beh?et’s disease and epistasis between HLA-B*51 and ERAP1, Nat Genet 45:202–207, 2013.
Kone-Paut I, Shahram F, Darce-Bello M, et al: Consensus classification criteria for paediatric Beh?et’s disease from a prospective observational cohort: PEDBD, Ann Rheum Dis 75:958–964, 2016.
Mason RM, Barnes CG: Beh?et’s syndrome with arthritis, Ann Rheum Dis 28:95–103, 1969.
Mizuki N, Meguro A, Ota M, et al: Genome-wide association studies identify IL23R IL12RB2 and IL10 as Beh?et’s disease susceptibility loci, Nat Genet 42:703–706, 2010.
Oeuz AK, Yilmaz ST, Oyg?r CD, et al: Beh?et’s: a disease or a syndrome? Answer from an expression profiling study, PLoS ONE 11(12):e0149052, 2015.
Onal S, Kazokoglu H, Koc A, et al: Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh?et uveitis, Arch Ophthalmol 129(3):288–294, 2011.
Ozen S, Bilginer Y, Besbas N, et al: Beh?et disease: treatment of vascular involvement in children, Eur J Pediatr 169(4):427–430, 2010.
Remmers EF, Cosan F, Kirino Y, et al: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh?et’s disease, Nat Genet 42:698–702, 2010.
Saadoun D, Asli B, Wechsler B, et al: Long-term outcome of arterial lesions in Beh?et disease, Medicine (Baltimore) 91(1)118–24, 2012.
Takeuchi M, Kastner DL, Remmers EF: The immunogenetics of Beh?et’s disease: a comprehensive review, J Autoimmun 64:137–148, 2015.
Yazici H, Ugurlu S, Seyahi E: Beh?et syndrome: Is it one condition? Clin Rev Allergy Immunol 43:275–280, 2012.
Akar S, Yuksel F, Tunca M, et al: Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era, Medicine (Baltimore) 91:131–136, 2012.
Aksentijevich I, Masters SL, Ferguson PJ, et al: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist, N Engl J Med 360:2426–2437, 2009.
Bader-Meunier B, Florkin B, Sibilia J, et al: SOFREMIP (Soci?t? Francophone pour la Rhumatologie et les Maladies Inflammatoires en P?diatrie); CRI (Club Rhumatismes et Inflammations): mevalonate kinase deficiency: a survey of 50 patients, Pediatrics 128:e152–e159, 2011.
Ben-Ami T, Revel-Vilk S, Brooks R, et al: Extending the clinical phenotype of adenosine deaminase 2 deficiency, J Pediatr 177:316–320, 2016.
Boisson B, Laplantine E, Dobbs K, et al: Human HOIP and LUBAC deficiency underlies autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia, J Exp Med 212(6):939–951, 2015.
Bulua AC, Mogul DB, Aksentijevich I, et al: Efficacy of etanercept in the tumor necrosis factor receptor–associated periodic syndrome: a prospective, open-label, dose-escalation study, Arthritis Rheum 64:908–913, 2012.
Canna SW, de Jesus AA, Gouni S, et al: An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome, Nat Genet 46(10):1140–1146, 2014.
Carneiro S, Sampaio-Barros PD: SAPHO syndrome, Rheum Dis Clin North Am 39: 401–418, 2013.
Chae JJ, Cho Y-H, Lee G-S, et al: Gain-of-function mutations induce NLRP3 protein-independent interleukin-1? activation and severe autoinflammation in mice, Immunity 34:755–768, 2011.
Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al: Mutation in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD), Blood 124:2867–2871, 2014.
Crow YJ, Casanova JL: STING-associated vasculopathy with onset in infancy—a new interferonopathy, N Engl J Med 371:568–572, 2014.
Dagan E, Gershoni-Baruch R, Khatib I, et al: MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA, Rheumatol Int 30:633–636, 2010.
Elkan PN, Pierce SB, Segel R, et al: Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy, N Engl J Med 370:917–927, 2014.
Fritz J, Tzairbatchev N, Claussen CD, et al: Chronic recurrent multifocal osteomyelitis: comparison of whole-body MR imaging with radiography and correlation with clinical and laboratory data, Radiology 252(3):842–851, 2009.
Garavello W, Pignataro L, Gaini L, et al: Tonsillectomy in children with periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome, J Pediatr 159: 138–142, 2011.
Gattorno M, Obici L, Cattalini M, et al: Canakinumab treatment for patients with active recurrent or chronic TNF receptor–associated periodic syndrome (TRAPS): an open-label, phase II study, Ann Rheum Dis 76(1):173–178, 2017.
Hashkes PJ, Toker O: Autoinflammatory syndromes, Pediatr Clin North Am 59:447–470, 2012.
Herlin T, Fiirgaard B, Bjerre M, et al: Efficacy of anti-IL-1 treatment in Majeed syndrome, Ann Rheum Dis 72:410–413, 2013.
Jesus AA, Goldbach-Mansky R: IL-1 blockade in autoinflammatory syndromes, Annu Rev Med 65:223–244, 2014.
La Regina M, Orlandini F, Manna R: Autoimflammatory diseases: a possible cause of thrombosis? Thromb J 13:19, 2015.
Lachmann HJ, Papa R, Gerhold K, et al: Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS, and the Eurofever Project. The phenotype of TNF receptor–associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry, Ann Rheum Dis 73(12):2160–2167, 2014.
Lantto U, Koivunen P, Tapiainen T, Renko M: Long-tern outcome of classic and incomplete PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and adenitis) syndrome after tonsillectomy, J Pediatr 179:172–177, 2016.
Levy M, Arion A, Berrebi D, et al: Severe early-onset colitis revealing mevalonate kinase deficiency, Pediatrics 132:e779–e783, 2013.
Liu Y, Jesus B, Marrero D, et al: Activated STING in a vascular and pulmonary syndrome, N Engl J Med 371:507–518, 2014.
Liu Y, Ramot Y, Torrelo A, et al: Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity, Arthritis Rheum 64:895–907, 2012.
Manukyan G, Aminov R: Update on pyrin functions and mechanisms of familial Mediterranean fever, Front Microbiol 7:456, 2016.
Marrakchi S, Guigue P, Renshaw BR, et al: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis, N Engl J Med 365(7):620–628, 2011.
Martin-Nalda A, Roca I, Fontecha CG, et al: Chronic recurrent multifocal osteomyelitis and thalidomide in chronic granulomatous disease, Pediatrics 138(2):e20154017, 2016.
Padeh S, Gerstein M, Berkun Y: Colchicine is a safe drug in children with familial Mediterranean fever, J Pediatr 161:1142–1146, 2012.
Sanchez GA, de Jesus A, Goldbach-Mansky R: Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation, Rheum Dis Clin North Am 39:701–734, 2013.
Sibley CH, Plass N, Snow J, et al: Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra, Arthritis Rheum 64:2375–2386, 2012.
Smith EJ, Allantaz F, Bennett L, et al: Clinical, molecular, and genetic characteristics of PAPA syndrome: a review, Curr Genomics 11:519–527, 2010.
Stern SM, Ferguson PJ: Autoinflammatory bone diseases, Rheum Dis Clin North Am 39:735–749, 2013.
Stojanov S, Lapidus S, Chitkara P, et al: Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade, Proc Natl Acad Sci USA 108(7148):7153, 2011.
Sfriso P, Caso F, Tognon S, et al: Blau syndrome, clinical and genetic aspects, Autoimmun Rev 12(1):44–51, 2012.
Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al: Paediatric Rheumatology International Trials Organisation and Eurofever Project. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever Registry, Arthritis Rheumatol 68(11):2795–2805, 2016.
Verbsky JW: Monogenic causes of inflammatory disease in rheumatology, Curr Opin Rheumatol 24:506–514, 2012.
Vigo G, Zulian F: Periodic fevers with aphthous stomatitis, pharyngitis, and adenitis (PFAPA), Autoimmun Rev 12:52–55, 2012.
Wurster VM, Carlucci JG, Feder HM Jr, et al: Long-term follow-up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome, J Pediatr 159:958–964, 2011.
Zerwas S, Larsen JT, Petersen L, et al: Eating disorders, autoimmune, and autoinflammatory disease, Pediatrics 140(6):e2016089, 2017.
Zhou Q, Lee G-S, Brady J, et al: A hypermorphic missense mutation in PLCG2, encoding phospholipase C?2, causes a dominantly inherited autoinflammatory disease with immunodeficiency, Am J Hum Genet 91:713–720, 2012.
Zhou Q, Yang D, Ombrello AK, et al: Early-onset stroke and vasculopathy associated with mutations in ADA2, N Engl J Med 370:911–920, 2014.
Ando Y, Coelho T, Berk JL, et al: Guideline of transthyretin-related hereditary amyloidosis for clinicians, Orphanet J Rare Dis 8:31, 2013.
Iizuka M, Sagara S, Etou T: Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with Crohn’s disease, Inflamm Bowel Dis 17:E67–E68, 2011.
Immonen K, Savolainen A, Kautiainen H, et al: Long-term outcome of amyloidosis associated with juvenile idiopathic arthritis, J Rheumatol 35:907–912, 2008.
Inoue D, Arima H, Kawanami C, et al: Excellent therapeutic effect of tocilizumab on intestinal amyloid A deposition secondary to active rheumatoid arthritis, ClinRheumatol 29:1195–1197, 2010.
Kobak S, Oksel F, Kabasakal Y, et al: Ankylosing spondylitis-related secondary amy¬loidosis responded well to etanercept: a report of three patients, ClinRheumatol 12:2191–2194, 2007.
Kuroda T, Wada Y, Kobayashi D, et al: Effective anti-TNF-? therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis, J Rheumatol 36:2409–2415, 2009.
Lachmann HJ, Goodman HB, Gilbertson JA, et al: Natural history and outcome in systemic AA amyloidosis, N Engl J Med 356:2361–2371, 2007.
Meinzer U, Quartier P, Alexandra JF, et al: Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature, Semin Arthritis Rheum 41(2):265–271, 2011.
Nakamura T, Higashi S, Tomoda K, et al: Etanercept can induce resolution or renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis, ClinRheumatol 29:1395–1401, 2010.
Obici L, Meini A, Cattalini M, et al: Favourable and sustained response to anakinra in tumour necrosis factor receptor–associated periodic syndrome (TRAPS) with or without AA amyloidosis, Ann Rheum Dis 70(8):1511–1512, 2011.
Okuda Y, Talasugi K: Successful use of a humanized anti-interleukin 6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis, Arthritis Rheum 54:2997–3000, 2006.
Ombrello AK, Aksentijevich I: AA amyloidosis in amyloid and related diseases, CurrClinPathol 31–53, 2015.
Plante-Bordeneuve V: Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy, J Neurol 261:1227–1233, 2014.
Singh G, Kumari N, Aggarwal A, et al: Prevalence of subclinical amyloidosis in ankylosing spondylitis, J Rheumatol 34:371–373, 2007.
Sipe JD, Benson MD, Buxbaum JN, et al: Amyloid fibril proteins and amyloidosis: clinical classification International Society of Amyloidosis Nomenclature Guidelines, Amyloid 23:209–213, 2016.
Thornton BD, Hoffman HM, Bhat A, et al: Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin-1 receptor antagonist, Am J Kidney Dis 49(3):477–481, 2007.
Arastegui JI, Arnal C, Merino R, et al: NOD2 gene–associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort, Arthritis Rheum 56(11):3805–3813, 2007.
Baumann RJ, Robertson WC Jr: Neurosarcoid presents differently in children than in adults, Pediatrics 112:e480–e486, 2003.
Beegle SH, Barba K, Gobunsuy R, et al: Current and emerging pharmacological treatments for sarcoidosis: a review, Drug Des Devel Ther 7:325–338, 2013.
Dempsey OJ, Paterson EW, Kerr KM, et al: Sarcoidosis, BMJ 339:620–625, 2009.
Fretzayas A, Moustaki M, Vougiouka O: The puzzling clinical spectrum and course of juvenile sarcoidosis, World J Pediatr 7(2):103–110, 2011.
Gedalia A, Khan TA, Shetty AK, et al: Childhood sarcoidosis: louisiana experience, Clin Rheumatol 35(7):1879–1884, 2016.
Guerra JR, Alderuccio JP, Sandhu J, et al: Granulomatous tattoo reaction in a young man, Lancet 382:284, 2013.
Ho LP, Urban BC, Thickett DR, et al: Deficiency of a subset of T cells with immunoregulatory properties in sarcoidosis, Lancet 365:1062–1072, 2005.
Hoffman AL, Milman N, Byg K-E: Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children, Acta Paediatr 93:30–36, 2004.
Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis, N Engl J Med 357:2153–2165, 2007.
La Torre F, Lapadula G, Cantarini L, et al: Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature, Clin Rheumatol 34(2):391–395, 2015.
Martin TM, Zhang Z, Kurz P, et al: The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity, Arthritis Rheum 60(2):611–618, 2009.
Newman LS, Rose CS, Bresnitz EA, et al: A case control etiologic study of sarcoidosis: environmental and occupational risk factors, Am J Respir Crit Care Med 170:1324–1330, 2004.
Ros? CD, Ar?stegui JI, Martin TM, et al: NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: a study of an international registry and a national cohort in Spain, Arthritis Rheum 60(6):1797–1803, 2009.
Rosu CD, Pans S, Casteels I, et al: Blau syndrome: cross-sectional data from a multicenter study of clinical, radiological, and functional outcomes, Rheumatology 54(6):1008–1016, 2015.
Shetty AK, Gedalia A: Childhood sarcoidosis: a rare but fascinating disorder, Pediatr Rheumatol Online J 6:16, 2008.
Spagnolo P, du Bois RM: Genetics of sarcoidosis, Clin Dermatol 25:242–249, 2007.
Valerye D, Prasse A, Nunes H, et al: Sarcoidosis, Lancet 383:1155–1167, 2014.
Von Bartheld MB, Dekkers OM, Szlubowski A, et al: Endosonography vs conventional bronchoscopy for the diagnosis of sarcoidosis, JAMA 309(23):2457–2464, 2013
Chen S, Dong Y, Kiuchi M, et al: Coronary artery complication in Kawasaki disease and the importance of early intervention, JAMA Pediatr 170(12):1156–1163, 2016.
Dionne A, Ibrahim R, Gebhard C, et al: Coronary wall structure changes in patients with Kawasaki disease: new insights from optical coherence tomography (OCT), J Am Heart Assoc 4:e001939, 2015.
Friedman KG, Gauvreau K, Hamaok-Okamoto A, et al: Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the US population, J Am Heart Assoc 5(9):2016.
Gong GWK, McCrindle BW, Ching JC, Yeung RSM: Arthritis presenting during the acute phase of Kawasaki disease, J Pediatr 148:800–805, 2001.
Gordon JB, Daniels LB, Kahn AM, et al: The spectrum of cardiovascular lesions requiring intervention in adults after Kawasaki disease, JACC CardiovascInterv 9:687–696, 2016.
Gorman KM, Gavin PJ, Capra L: Bacillus-Calmette-Gu?rin scar erythema: “haloing” the diagnosis in Kawaski disease, J Pediatr 167:774, 2015.
Haddock ES, Calame A, Shimizu C, et al: Psoriasiform eruptions during Kawasaki diasease (KD): a distinct phenotype, J Am AcadDermatol 75(1):69–76, 2016.
Hoshino S, Tsuda E, Yamada O: Characteristics and fate of systemic artery aneurysm after Kawasaki disease, J Pediatr 167:108–112, 2015.
Kanegaye JT, Van Cott E, Tremoulet AH, et al: Lymph-node-first presentation of Kawasaki disease compared with bacteria; cervical adenitis and typical Kawasaki disease, J Pediatr 162:1259–1269, 2013.
Kobayashi T, Saji T, Otani T, et al: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open label, blinded endpoints trial, Lancet 379(9826):1613–1620, 2012.
Makino N, Nakamura Y, Yashiro M, et al: Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey, J Epidemiol 25(3):239–245, 2015.
McCrindle BW, Rowley A, Newburger JW, et al: Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association, Circulation 135(17):e927–e999, 2017.
McCrindle BW, Tierney ESS: Acute treatment for Kawasaki disease: challenges for current and future therapies, J Pediatr 184:7–10, 2017.
Newburger JW, Sleeper LA, McCrindle BW, et al: Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease, N Engl J Med 356:663–675, 2007.
Nomura Y, Arata M, Koriyama C, et al: A severe form of Kawasaki disease presenting with only fever and cervical lymphadenopathy at admission, J Pediatr 156:786–791, 2010.
Okuda Y, Nochioka K, Sakakibara H, et al: National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA, ClinRheumatol 36:413–419, 2017.
Orenstein JM, Shulman ST, Fox LM, et al: Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study, PLoS ONE 7(6):e38998, 2012.
Salgado AP, Ashouri N, Berry EK, et al: High risk of coronary artery aneurysms in infants younger than 6 months of age with Kawasaki disease, J Pediatr 185:112–116, 2017.
Sleeper L, Minich LL, McCrindle BM, et al: Evaluation of Kawasaki disease risk scoring systems for intravenous immunoglobulin resistance, J Pediatr 158:831–835, 2011.
Son MB, Gauvreau K, Burns JC, et al: Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study, J Pediatr 158:644–649, 2011.
Song E, Kajon AE, Wang H, et al: Clinical and virologic characteristics may aid distinction of acute adenovirus disease from Kawasaki disease with incidental adenovirus detection, J Pediatr 170:325–330, 2016.
Tissandier C, Lang M, Lusson JR, et al: Kawasaki shock syndrome complicating a recurrence of Kawasaki disease, Pediatrics 134:e1695–e1699, 2014.
Tremoulet AH, Jain S, Jaggi P, et al: Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial, Lancet 383:1731–1738, 2014.
Wardle AJ, Connolly GM, Saeger MJ, Tulloh RMR: Corticosteroids for the treatment of Kawasaki disease in children (review), Cochrane Database Syst Rev (1):CD011188, 2017.
Eleftheriou D, Brogan PA: Therapeutic advances in the treatment of vasculitis, Pediatr Rheumatol Online J 14(1):26, 2016.
Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides: proposal of an international consensus conference, Arthritis Rheum 37:187–192, 1994.
Jennette JC, Falk RJ: 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides, Arthritis Rheum 65(1):1–11, 2013.
Jones RB, Tervaert JWC, Hauser T, et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, N Engl J Med 363(3):211–226, 2010.
Ozen S: Update in paediatric vasculitis, Best Pract Res Clin Rheumatol 23(5):679–688, 2009.
Ozen S, Ruperto N, Dillon MJ, et al: EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides, Ann Rheum Dis 65:936–941, 2006.
Wahezi DM, Gomes WA, Howite NT: Cranial nerve involvement with juvenile polyarteritis nodosa: clinical manifestations and treatment, Pediatrics 126(3):e719–e722, 2010.
Weiss PF: Pediatric vasculitis, Pediatr Clin North Am 49(2):407–423, 2012.
Chartapisak W, Opastiraku S, Willis NS, et al: Prevention and treatment of renal disease in Henoch-Sch?nlein purpura: a systematic review, Arch Dis Child 94:132–137, 2009.
Coulombe J, Jean SE, Hatami A, et al: Pigmented purpuric dermatosis: clinicopathologic characterization in a pediatric series, Pediatr Dermatol 32(3):358–362, 2015.
Dayanir YO, Akdilli A, Karaman CZ, et al: Epididymoorchitis mimicking testicular torsion in Henoch-Sch?nlein purpura, Eur Radiol 11:2267–2269, 2011.
Dudley JS: Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Sch?nlein purpura (HSP), Arch Dis Child 98(10):756–763, 2013.
He X, Yu C, Zhao P, et al: The genetics of Henoch-Sch?nlein purpura: a systematic review and meta-analysis, Rheumatol Int 33:1387–1395, 2013.
Jauhola O, Ronkainen J, Koskimies O, et al: Clinical course of extrarenal symptoms in HSP: a 6-month prospective study, Arch Dis Child 95:871–876, 2010.
Jauhola O, Ronkainen J, Koskimies O, et al: Renal manifestations of HSP in a 6-month prospective study of 223 children, Arch Dis Child 95:877–882, 2010.
Jauhola O, Ronkainen J, Koskimies O, et al: Outcome of Henoch-Sch?nlein purpura 8 yr after treatment with a placebo or prednizone at disease onset, Pediatr Nephrol 28:933–939, 2012.
Kanaan N, Mourad G, Thervet E: Recurrence and graft loss after kidney transplantation for Henoch-Sch?nlein purpura nephritis: a multicenter analysis, Clin J Am Soc Nephrol 6:1768–1772, 2011.
Jennette JC, Falk RJ: Revised International Chapel Hill Consensus Conference nomenclature of vasculitides, Arthritis Rheum 65(1):1–11, 2013.
Mir S, Yavascan O, Mutlubas F, et al: Clinical outcome in children with Henoch-Sch?nlein nephritis, Pediatr Nephrol 22:64–70, 2007.
Ozen S, Pistorio A, Iusan SM, et al: EULAR/PRINTO/PRES criteria for Henoch-Sch?nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II. Final classification criteria, Ann Rheum Dis 69:798–806, 2010.
Ronkainen J, Koskimies O, Ala-Houhala M, et al: Early prednisone therapy in Henoch-Sch?nlein purpura: a randomized, double-blind, placebo-controlled trial, J Pediatr 149:241–247, 2006.
Weiss PF, Feinstein JA, Luan X, et al: Effects of corticosteroid on Henoch-Sch?nlein purpura: a systematic review, Pediatrics 120:1079–1087, 2007.
Weiss PF, Klink AJ, Hexem K, et al: Variation in inpatient therapy and diagnostic evaluation of children with Henoch-Sch?nlein purpura, J Pediatr 155:812–818, 2009.
Weiss PF, Klink AJ, Localio R, et al: Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Sch?nlein purpura, Pediatrics 126:674–6781, 2010.
Yang YS, Yu HH, Chiang BL: The diagnosis and classification of Henoch-Sch?nlein purpura: an updated review, Autoimmun Rev 13:355–358, 2014.
Alibaz-Oner F, Aydin SZ, Direskeneli H: Advances in the diagnosis, assessment and outcome of Takayasu’s arteritis, Clin Rheumatol 32:541–546, 2013.
Brunner J, Feldman BM, Tyrrell PN, et al: Takayasu arteritis in children and adolescents, Rheumatology 1806–1814, 2010.
Batu ED, S?nmez HE, Hazrolan T, et al: Tocilizumab treatment in childhood Takayasu arteritis: case series of four patients and systematic review of the literature, Semin Arthritis Rheum 46(4):529–535, 2017.
Cakar N, Yalcinkaya F, Duzova A, et al: Takayasu arteritis in children, J Rheumatol 35:913–919, 2008.
Filocamo G, Buoncompagni A, Viola S, et al: Treatment of Takayasu’s arteritis with tumor necrosis factor antagonists, J Pediatr 153:432–434, 2008.
Forsey J, Dhandayuthapani G, Hamilton MCK, et al: Takayasu arteritis: key clinical factors for early diagnosis, Arch Dis Child Educ Pract Ed 96:176–182, 2011.
Kalangos A, Christenson JT, Cikirikcioglu M, et al: Long-term outcome after surgical intervention and interventional procedures for the management of Takayasu’s arteritis in children, J Thorac Cardiovasc Surg 132:656–664, 2006.
Liang P, Tan-Ong M, Hoffman GS: Takayasu’s arteritis: vascular interventions and outcomes, J Rheumatol 31:102–106, 2004.
Maksimowicz-McKinnon K, Clark TM, Hoffman GS: Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients, Arthritis Rheum 56:1000–1009, 2007.
Ozen S, Duzova A, Bakkaloglu A, et al: Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate, J Pediatr 150:72–76, 2007.
Park MC, Lee SW, Park YB, et al: Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification, Scand J Rheumatol 34:284–292, 2005.
Park MC, Lee SW, Park YB, et al: Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis, Rheumatology (Oxford) 45:545–548, 2006.
Saadoun D, Lambert M, Mirault T, et al: Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience, Circulation 125:813–819, 2012.
Dedeoglu F, Sundel RP: Vasculitis in children, Rheum Dis Clin North Am 33:555–583, 2007.
Eleftheriou D, Dillon M, Tullus K, et al: Systemic polyarteritis nodosa in the young: a single center experience over 32 years, Arthritis Rheum 65(9):2476–2485, 2013.
Elkan PN, Pierce SB, Segel R, et al: Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy, N Engl J Med 370:921–930, 2014.
Guillevin L, Lhote F, Gayraud M, et al: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients, Medicine (Baltimore) 75:17–29, 1996.
Liu Y, Ramot Y, Torrelo A, et al: Mutations in proteasome subunit ? type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity, Arthritis Rheum 64(3):895–907, 2012.
Liu Y, Jesus AA, Marrero B, et al: Activated STING in a vascular and pulmonary syndrome, N Engl J Med 371(6):507–518, 2014.
Nakamura T, Kanazawa N, Ikeda T, et al: Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria, Arch Dermatol Res 301:117–121, 2009.
Ozen S, Pistorio A, Iusan SM, et al: EULAR/PRINTO/PRES criteria for Henoch-Sch?nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II. Final classification criteria, Ann Rheum Dis 69:798–806, 2010.
Reddy VB, Schloemer N: Polyarteritis nodosa in a 9-year-old boy, J Pediatr 162:216, 2013.
Yalcinkaya F, Ozcakar B, Kasapcoupur O, et al: Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa, J Pediatr 151:675–678, 2007.
Akikusa JD, Schneider R, Harvey EA, et al: Clinical features and outcome of pediatric Wegener’s granulomatosis, Arthritis Rheum 57:837–844, 2007.
Berden A, Goceroglu A, Jayne D, et al: Diagnosis and management of ANCA-associated vasculitis, BMJ 344:40–44, 2012.
Bosch X, Guilabert A, Espinosa G, et al: Treatment of antineutrophil cytoplasmic antibody–associated vasculitis, JAMA 298:655–668, 2007.
Cabral DA, Canter DL, Muscal E, et al: Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe cohort study, Arthritis Rheumatol 68(10):2514–2526, 2016.
Cabral DA, Uribe AG, Benseler S, et al: Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood, Arthritis Rheum 60(11):3413–3424, 2009.
Falk RJ, Gross WL, Guillevin L, et al: Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis, Arthritis Rheum 63(4):863–864, 2011.
Finkielman JD, Merkel PA, Schroeder D, et al: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis, Ann Intern Med 147:611–619, 2007.
Gendelman S, Zeft A, Spaulding SJ: Childhood-onset eosinophillic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort, J Rheumatol 40:929–935, 2013.
Guillevin L, Pagnoux C, Karras A, et al: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis, N Engl J Med 371:1771–1780, 2014.
Jayne DR, Gaskin G, Rasmussen N, et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis, J Am Soc Nephrol 18(7):2180–2188, 2007.
Levine D, Akikusa J, Manson D, et al: Chest CT findings in pediatric Wegener’s granulomatosis, Pediatr Radiol 37:57–62, 2007.
Lyons PA, Rayner TF, Trivedi S, et al: Genetically distinct subsets within ANCA-associated vasculitis, N Engl J Med 367(3):214–222, 2012.
Mahr A, Moosig F, Neumann T, et al: Eosinophilic granulomatosis with polyantiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management, Curr Opin Rheumatol 26(1):16–23, 2014.
Pagnoux C, Mahr A, Hamidou MA, et al: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis, N Engl J Med 359:2790–2802, 2008.
Simmon E, Tramma D, Bowen C, et al: ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features—outcome, Pediatr Nephrol 27:1911–1920, 2012.
Sinico RA, Di Toma L, Radice A: Renal involvement in anti-neutrophil cytoplasmic autoantibody–associated vasculitis, Autoimmun Rev 12:477–482, 2013.
Siomou E, Tramma D, Bowen C, et al: ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features–outcome, Pediatr Nephrol 10:1911–1920, 2012.
Specks U, Merkel PA, Seo P, et al: Efficacy of remission-induction regimens for ANCA-associated vasculitis, N Engl J Med 369:417–426, 2013.
Stone JH, Merkel PA, Spiera R, et al: Rituximab versus cyclophosphamide for ANCA-associated vasculitis, N Engl J Med 363:221–232, 2010.
Wechsler ME, Akuthota P, Jayne D, et al: Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis, N Engl J Med 376(20):1921–1932, 2017.
Abril A: Churg-Strauss syndrome: an update, Curr Rheumatol Rep 13:489–495, 2011.
Benseler SM: Central nervous system vasculitis in children, Curr Rheumatol Rep 8:442–449, 2006.
Cassidy JT, Petty RE: Systemic vasculitis. In Textbook of pediatric rheumatology, ed 5, Philadelphia, 2005, Elsevier Saunders.
Dedeoglu F, Sundel RP: Vasculitis in children, Rheum Dis Clin North Am 33:555–583, 2007.
Gray PEA, Bock A, Ziegler DS, et al: Neonatal Sweet syndrome: a potential marker of serious systemic illness, Pediatrics 129(5):e1333–e1359, 2012.
Gowdie P, Twitt M, Benseler SM: Primary and secondary central nervous system vasculitis, J Child Neurol 27(11):1448–1459, 2012.
Van Mater H: Pediatric inflammatory brain diseases: a diagnostic approach, Curr Opin Rheumatol 26(5):553–561, 2014.
Anthony KK, Schanberg LE: Assessment and management of pain syndromes and arthritis painin children and adolescents, Rheum Dis Clin North Am 33:625–660, 2007.
Clinch J, Eccleston C: Chronic musculoskeletal pain in children: assessment and management, Rheumatology (Oxford) 48:466–474, 2009.
Connelly MA, Schanberg LE: Evaluating and managing pediatric musculoskeletal pain in primary care. In Walco G, Goldschneider K, Berde A, editors: Pain in children: a practical guide for primary care, New York, 2008, Humana Press.
Liossi C, Howard RF: Pediatric chronic pain: biopsychosocial assessment and formulation, Pediatrics 138(5):e20160331, 2016.
Scharff L, Langan N, Rotter N, et al: Psychological, behavioral, and family characteristics of pediatric patients with chronic pain: a 1-year retrospective study and cluster analysis, Clin J Pain 21:432–438, 2005.
Stahl M, Kautiainen H, El-Metwally A, et al: Non-specific neck pain in schoolchildren: prognosis and risk factors for occurrence and persistence—a 4-year follow-up study, Pain 137:316–322, 2008.
Tobias JH, Deere K, Palmer S, et al: Joint hypermobility is a risk factor for musculoskeletal pain during adolescence, Arthritis Rheum 65:1107–1115, 2013.
Friedland O, Haskes PJ, Jaber L, et al: Decreased bone speed of sound in children with growing pains measured by quantitative ultrasound, J Rheumatol 32:1354–1357, 2005.
Hashkes PJ, Friedland O, Jaber L, et al: Decreased pain threshold in children with growing pains, J Rheumatol 31:610–613, 2004.
Lowe RM, Hashkes PJ: Growing pains: a noninflammatory pain syndrome of early childhood, Nat Clin Pract Rheumatol 4:542, 2008.
Pathiran S, Champion D, Jaaniste T, et al: Somatosensory test responses in children with growing pains, J Pain Res 4:393–400, 2011.
Walters AS, Gabelia D, Frauscher B: Restless legs syndrome (Willis-Ekbom disease) and growing pains: are they the same thing? A side-by-side comparison of the diagnostic criteria for both and recommendations for future research, Sleep Med 14:1247–1252, 2013.
Oaklander AL, Fields HL: Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol 65:629–638, 2009.
Oaklander AL, Herzog ZD, Downs HM, et al: Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia, Pain 154:231023–231026, 2013.
Oaklander AL, Klein MM: Evidence of small-fiber polyneuropathy in unexplained juvenile-onset, widespread pain syndromes, Pediatrics 131(4):e1091–e1100, 2013.
Paticoff J, Valovska A, Nedeljkovic SS, et al: Defining a treatable cause of erythromelalgia: acute adolescent autoimmune small-fiber axonopathy, Pain Med 104:438–441, 2007.
American Pain Society: Guidelines for the management of fibromyalgia syndrome pain in adults and children, Glenview IL, 2005, American Pain Society.
Arnold LM, Schikler KN, Bateman L, et al: Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study, Pediatr Rheumatol 14:46–57, 2016.
Clauw DJ: Fibromyalgia: a clinical review, JAMA 311:1547–1554, 2014.
Derry S, Cording M, Wiffen PJ, et al: Pregabalin for pain in fibromyalgia in adults (review), Cochrane Database Syst Rev (9):CD011790, 2016.
Kashikar-Zuck S, Parkins IS, Graham TB, et al: Anxiety, mood, and behavioral disorders among pediatric patients with juvenile fibromyalgia syndrome, Clin J Pain 24:620–626, 2008.
Kashikar-Zuck S, Ting TV, Arnold LM, et al: Cognitive-behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial, Arthritis Rheum 64:297–305, 2012.
Maia MM, Gualano B, Sa-Pinto AL, et al: Juvenile fibromyalgia syndrome: blunted heart rate response and cardiac autonomic dysfunction, Semin Arthritis Rheum 46:338–343, 2016.
Oaklander AL, Herzog ZD, Downs HM, et al: Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia, Pain 154(11):2310–2316, 2013.
Swain NF, Kashikar-Zuck S, Graham TB, et al: Tender point assessment in juvenile primary fibromyalgia syndrome, Arthritis Rheum 53:785–787, 2005.
Ting TV, Barnett K, Lynch-Jordan A, et al: 2010 American College of Rheumatology Adult Fibromyalgia Criteria for use in an adolescent female population with juvenile fibromyalgia, J Pediatr 169:181–187, 2016.
Barrett MJ, Barnett PLJ: Complex regional pain type 1, Pediatr Emerg Care 32(3): 185–188, 2016.
Berde C, Lebel A: Complex regional pain syndromes in children and adolescents, Anesthesiology 102(2):252–255, 2005.
Borucki AN, Greco CD: An update on complex regional pain syndromes in children and adolescents, Curr Opin Pediatr 27:448–452, 2015.
Goebel A, Baranowski A, Maurer K, et al: Intravenous immunoglobulin treatment of the complex regional pain syndrome, Ann Intern Med 152:152–158, 2010.
Goh EL, Chidambaram S: Complex regional pain syndrome: a recent update, Burns Trauma 5:2, 2017.
Harden RN, Oaklander AL, Burton AW, et al: Complex regional pain syndrome: practical diagnostic and treatment guidelines, Pain Med 14:180–229, 2013.
Oaklander AL, Fields HL: Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy, Ann Neurol 65:629–638, 2009.
Stanton-Hicks M: Plasticity of complex regional pain syndrome (CRPS) in children, Pain Med 11:1216–1223, 2010.
Wilder RT: Management of pediatric patients with complex regional pain syndrome, Clin J Pain 22:443–448, 2006.
Cook-Norris RH, Tollefson MM, Cruz-Inigo AE, et al: Pediatric erythromelalgia: a retrospective review of 32 cases evaluated at Mayo Clinic over a 37-year period, J Am Acad Dermatol 66:416–423, 2011.
Dabby R: Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations, Curr Neurol Neurosci Rep 12:76–83, 2012.
Davis MDP, Rooke T: Erythromelalgia, Curr Treat Options Cardiovasc Med 8:153–165, 2006.
Huh S, Jung K, Eun LY, et al: Erythromelalgia with a linear pattern in a 12-year-old girl, Pediatr Int 57:706–797, 2015.
Paticoff J, Valovska A, Nedeljkovic SS, et al: Defining a treatable cause of erythromelalgia: acute adolescent autoimmune small-fiber axonopathy, Pain Med 104:438–441, 2007.
Pfund Z, Stankovics J, Decsi T, et al: Childhood steroid-responsive acute erythromelalgia with axonal neuropathy of large myelinated fibers: a dysimmune neuropathy?, Neuromuscul Disord 19:49–52, 2009.
Thomas J, Maramattom BV, Kuruvilla PM, Varghese J: Subcutaneous panniculitis like T cell lymphoma associated with erythromelalgia, J Postgrad Med 60(3):335–337, 2014.
Fernandes NF, Rozdeba PJ, Schwartz RA, et al: Pityriasislichenoides et varioliformisacuta: a disease spectrum, Int J Dermatol 49:257–261, 2010.
Giancane G, Diggle CP, Legger EG, et al: Primary hypertrophic osteoarthropathy: an update on patient features and treatment, J Rheumatol 42:2211–2214, 2015.
Jayakar BA, Abelson AG, Yao Q: Treatment of hypertrophic osteoparthropathy with zoledronic acid: case report and review of the literature, Semin Arthritis Rheum 41:291–296, 2011.
Duerinckx JF: Case report: subacute synovitis of the knee after a rose thorn injury: unusual clinical picture, ClinOrthopRelat Res 466:3138–3142, 2008.
Patel AM, Brown AG, Galambos C, Hirsch R: Pediatric pigmented villonodular synovitis mimicking a septic hip, J ClinRheumatol 16:71–73, 2010.
Uihlein LC, Brandling-Bennett HA, Lio PA, et al: Sweet syndrome in children, PediatrDermatol 29:38–44, 2012.
Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martinez A: Sweet syndrome: a review and update, ActasDermosifiliogr 107:369–378, 2016.
